Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling

  1. Brian Czaya
  2. Kylie Heitman
  3. Isaac Campos
  4. Christopher Yanucil
  5. Dominik Kentrup
  6. David Westbrook
  7. Orlando Gutierrez
  8. Jodie L Babitt
  9. Grace Jung
  10. Isidro B Salusky
  11. Mark Hanudel
  12. Christian Faul  Is a corresponding author
  1. David Geffen School of Medicine at UCLA, United States
  2. University of Alabama at Birmingham, United States
  3. Massachusetts General Hospital, United States

Abstract

Elevations in plasma phosphate concentrations (hyperphosphatemia) occur in chronic kidney disease (CKD), in certain genetic disorders, and following the intake of a phosphate-rich diet. Whether hyperphosphatemia and/or associated changes in metabolic regulators, including elevations of fibroblast growth factor 23 (FGF23) directly contribute to specific complications of CKD is uncertain. Here we report that similar to patients with CKD, mice with adenine-induced CKD develop inflammation, anemia and skeletal muscle wasting. These complications are also observed in mice fed high phosphate diet even without CKD. Ablation of pathologic FGF23-FGFR4 signaling did not protect mice on an increased phosphate diet or mice with adenine-induced CKD from these sequelae. However, low phosphate diet ameliorated anemia and skeletal muscle wasting in a genetic mouse model of CKD. Our mechanistic in vitro studies indicate that phosphate elevations induce inflammatory signaling and increase hepcidin expression in hepatocytes, a potential causative link between hyperphosphatemia, anemia and skeletal muscle dysfunction. Our study suggests that high phosphate intake, as caused by the consumption of processed food, may have harmful effects irrespective of pre-existing kidney injury, supporting not only the clinical utility of treating hyperphosphatemia in CKD patients but also arguing for limiting phosphate intake in healthy individuals.

Data availability

All data generated and analyzed during this study is available through Dryad.

The following data sets were generated

Article and author information

Author details

  1. Brian Czaya

    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, United States
    Competing interests
    No competing interests declared.
  2. Kylie Heitman

    Department of Medicine, University of Alabama at Birmingham, Birmingham, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5345-2727
  3. Isaac Campos

    Department of Medicine, University of Alabama at Birmingham, Birmingham, United States
    Competing interests
    No competing interests declared.
  4. Christopher Yanucil

    Department of Medicine, University of Alabama at Birmingham, Birmingham, United States
    Competing interests
    No competing interests declared.
  5. Dominik Kentrup

    Department of Medicine, University of Alabama at Birmingham, Birmingham, United States
    Competing interests
    No competing interests declared.
  6. David Westbrook

    Department of Medicine, University of Alabama at Birmingham, Birmingham, United States
    Competing interests
    No competing interests declared.
  7. Orlando Gutierrez

    Department of Medicine, University of Alabama at Birmingham, Birmingham, United States
    Competing interests
    Orlando Gutierrez, has received honoraria and grant support from Akebia and Amgen, grant support from GSK, honoraria from Ardelyx, Reata, and AstraZeneca, and serves on the Data Monitoring Committee for QED.
  8. Jodie L Babitt

    Division of Nephrology, Massachusetts General Hospital, Boston, United States
    Competing interests
    Jodie L Babitt, has ownership interest in Ferrumax Pharmaceuticals and has been a consultant for Incyte Corporation, and Alnylam Pharmaceuticals.
  9. Grace Jung

    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, United States
    Competing interests
    No competing interests declared.
  10. Isidro B Salusky

    Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, United States
    Competing interests
    No competing interests declared.
  11. Mark Hanudel

    Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, United States
    Competing interests
    No competing interests declared.
  12. Christian Faul

    Department of Medicine, University of Alabama at Birmingham, Birmingham, United States
    For correspondence
    cfaul@uabmc.edu
    Competing interests
    Christian Faul, has served as a consultant for Bayer and Calico Labs, and he is the founder and currently the CSO of a startup biotech company (Alpha Young LLC)u.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7512-0977

Funding

National Institutes of Health (F31-DK-117550)

  • Brian Czaya

National Institutes of Health (F31-DK-115074)

  • Christopher Yanucil

National Institutes of Health (R01-HL-128714; R01-HL-145528)

  • Christian Faul

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Dolores Shoback, University of California, San Francisco, United States

Ethics

Animal experimentation: All animal protocols and experimental procedures for adenine diet in FGFR4+/+ and FGFR4-/- mice, graded phosphate diets in FGFR4+/+ and FGFR4-/- mice, low phosphate diets in COL4A3+/+ and COL4A3-/- mice and primary hepatocyte isolations from wild-type C57BL/6J mice, were approved by the Institutional Animal Care and Use Committees (IACUC) at the University of Alabama Birmingham School of Medicine (#22089). All animals were maintained in a ventilated rodent-housing system with temperature-controlled environments (22-23{degree sign}C) with a 12-hour light/dark cycle and allowed ad libitum access to food and water. All protocols adhered to the Guide for Care and Use of Laboratory Animals to minimize pain and suffering. No animals were excluded from analysis.

Version history

  1. Received: October 17, 2021
  2. Preprint posted: October 22, 2021 (view preprint)
  3. Accepted: March 17, 2022
  4. Accepted Manuscript published: March 18, 2022 (version 1)
  5. Version of Record published: March 29, 2022 (version 2)

Copyright

© 2022, Czaya et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,856
    views
  • 267
    downloads
  • 18
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Brian Czaya
  2. Kylie Heitman
  3. Isaac Campos
  4. Christopher Yanucil
  5. Dominik Kentrup
  6. David Westbrook
  7. Orlando Gutierrez
  8. Jodie L Babitt
  9. Grace Jung
  10. Isidro B Salusky
  11. Mark Hanudel
  12. Christian Faul
(2022)
Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling
eLife 11:e74782.
https://doi.org/10.7554/eLife.74782

Share this article

https://doi.org/10.7554/eLife.74782

Further reading

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Christopher TA Lewis, Elise G Melhedegaard ... Julien Ochala
    Research Article

    Hibernation is a period of metabolic suppression utilized by many small and large mammal species to survive during winter periods. As the underlying cellular and molecular mechanisms remain incompletely understood, our study aimed to determine whether skeletal muscle myosin and its metabolic efficiency undergo alterations during hibernation to optimize energy utilization. We isolated muscle fibers from small hibernators, Ictidomys tridecemlineatus and Eliomys quercinus and larger hibernators, Ursus arctos and Ursus americanus. We then conducted loaded Mant-ATP chase experiments alongside X-ray diffraction to measure resting myosin dynamics and its ATP demand. In parallel, we performed multiple proteomics analyses. Our results showed a preservation of myosin structure in U. arctos and U. americanus during hibernation, whilst in I. tridecemlineatus and E. quercinus, changes in myosin metabolic states during torpor unexpectedly led to higher levels in energy expenditure of type II, fast-twitch muscle fibers at ambient lab temperatures (20 °C). Upon repeating loaded Mant-ATP chase experiments at 8 °C (near the body temperature of torpid animals), we found that myosin ATP consumption in type II muscle fibers was reduced by 77–107% during torpor compared to active periods. Additionally, we observed Myh2 hyper-phosphorylation during torpor in I. tridecemilineatus, which was predicted to stabilize the myosin molecule. This may act as a potential molecular mechanism mitigating myosin-associated increases in skeletal muscle energy expenditure during periods of torpor in response to cold exposure. Altogether, we demonstrate that resting myosin is altered in hibernating mammals, contributing to significant changes to the ATP consumption of skeletal muscle. Additionally, we observe that it is further altered in response to cold exposure and highlight myosin as a potentially contributor to skeletal muscle non-shivering thermogenesis.

    1. Cell Biology
    Jun Yang, Shitian Zou ... Xiaochun Bai
    Research Article

    Quiescence (G0) maintenance and exit are crucial for tissue homeostasis and regeneration in mammals. Here, we show that methyl-CpG binding protein 2 (Mecp2) expression is cell cycle-dependent and negatively regulates quiescence exit in cultured cells and in an injury-induced liver regeneration mouse model. Specifically, acute reduction of Mecp2 is required for efficient quiescence exit as deletion of Mecp2 accelerates, while overexpression of Mecp2 delays quiescence exit, and forced expression of Mecp2 after Mecp2 conditional knockout rescues cell cycle reentry. The E3 ligase Nedd4 mediates the ubiquitination and degradation of Mecp2, and thus facilitates quiescence exit. A genome-wide study uncovered the dual role of Mecp2 in preventing quiescence exit by transcriptionally activating metabolic genes while repressing proliferation-associated genes. Particularly disruption of two nuclear receptors, Rara or Nr1h3, accelerates quiescence exit, mimicking the Mecp2 depletion phenotype. Our studies unravel a previously unrecognized role for Mecp2 as an essential regulator of quiescence exit and tissue regeneration.